Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production.

Bissinger T, Fritsch J, Mihut A, Wu Y, Liu X, Genzel Y, Tan WS, Reichl U.

Vaccine. 2019 Apr 29. pii: S0264-410X(19)30528-6. doi: 10.1016/j.vaccine.2019.04.054. [Epub ahead of print]

PMID:
31047676
2.

Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.

Gränicher G, Coronel J, Pralow A, Marichal-Gallardo P, Wolff M, Rapp E, Karlas A, Sandig V, Genzel Y, Reichl U.

Vaccine. 2019 Apr 17. pii: S0264-410X(19)30481-5. doi: 10.1016/j.vaccine.2019.04.030. [Epub ahead of print]

PMID:
31005427
3.

High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.

Vázquez-Ramírez D, Jordan I, Sandig V, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035. doi: 10.1007/s00253-019-09694-2. Epub 2019 Feb 23.

4.

Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production.

Nikolay A, Léon A, Schwamborn K, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2018 Oct;102(20):8725-8737. doi: 10.1007/s00253-018-9275-z. Epub 2018 Aug 8.

5.

Vaccine Technology VI: Innovative and integrated approaches in vaccine development.

Palomares LA, Mukhopadhyay TK, Genzel Y, Lua LHL, Cox MMJ.

Vaccine. 2018 May 24;36(22):3061-3063. doi: 10.1016/j.vaccine.2018.03.077. Epub 2018 Apr 11. No abstract available.

PMID:
29655633
6.

High-cell-density cultivations to increase MVA virus production.

Vázquez-Ramírez D, Genzel Y, Jordan I, Sandig V, Reichl U.

Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9.

PMID:
29433897
7.

Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.

Rey-Jurado E, Tapia F, Muñoz-Durango N, Lay MK, Carreño LJ, Riedel CA, Bueno SM, Genzel Y, Kalergis AM.

Front Immunol. 2018 Jan 18;9:26. doi: 10.3389/fimmu.2018.00026. eCollection 2018. Review.

8.

Cell culture-based production of defective interfering particles for influenza antiviral therapy.

Wasik MA, Eichwald L, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2018 Feb;102(3):1167-1177. doi: 10.1007/s00253-017-8660-3. Epub 2017 Dec 5.

9.

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.

Tapia F, Jordan I, Genzel Y, Reichl U.

PLoS One. 2017 Aug 24;12(8):e0182553. doi: 10.1371/journal.pone.0182553. eCollection 2017.

10.

Propagation of Brazilian Zika virus strains in static and suspension cultures using Vero and BHK cells.

Nikolay A, Castilho LR, Reichl U, Genzel Y.

Vaccine. 2018 May 24;36(22):3140-3145. doi: 10.1016/j.vaccine.2017.03.018. Epub 2017 Mar 23.

11.

Ezrin and HNRNP expression correlate with increased virus release rate and early onset of virus-induced apoptosis of MDCK suspension cells.

Kluge S, Genzel Y, Laus K, Serve A, Pflugmacher A, Peschel B, Rapp E, Reichl U.

Biotechnol J. 2016 Oct;11(10):1332-1342. doi: 10.1002/biot.201600384.

PMID:
27581796
12.

Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.

Tapia F, Vázquez-Ramírez D, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32. doi: 10.1007/s00253-015-7267-9. Epub 2016 Jan 13. Review.

13.

Bioreactor concepts for cell culture-based viral vaccine production.

Gallo-Ramírez LE, Nikolay A, Genzel Y, Reichl U.

Expert Rev Vaccines. 2015;14(9):1181-95. doi: 10.1586/14760584.2015.1067144. Epub 2015 Jul 15. Review.

PMID:
26178380
14.

Vaccine Technology V: The art of taking vaccines to disease prevention.

Palomares LA, Buckland BC, Genzel Y, Cox MM.

Vaccine. 2015 Aug 20;33(35):4219-20. doi: 10.1016/j.vaccine.2015.06.098. Epub 2015 Jun 29. No abstract available.

PMID:
26133049
15.

Designing cell lines for viral vaccine production: Where do we stand?

Genzel Y.

Biotechnol J. 2015 May;10(5):728-40. doi: 10.1002/biot.201400388. Epub 2015 Apr 22. Review.

PMID:
25903999
16.

Monitoring changes in proteome during stepwise adaptation of a MDCK cell line from adherence to growth in suspension.

Kluge S, Benndorf D, Genzel Y, Scharfenberg K, Rapp E, Reichl U.

Vaccine. 2015 Aug 20;33(35):4269-80. doi: 10.1016/j.vaccine.2015.02.077. Epub 2015 Apr 16.

PMID:
25891398
17.

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis.

Lohr V, Hädicke O, Genzel Y, Jordan I, Büntemeyer H, Klamt S, Reichl U.

BMC Biotechnol. 2014 Jul 30;14:72. doi: 10.1186/1472-6750-14-72.

18.

The influence of cell growth and enzyme activity changes on intracellular metabolite dynamics in AGE1.HN.AAT cells.

Rath AG, Rehberg M, Janke R, Genzel Y, Scholz S, Noll T, Rose T, Sandig V, Reichl U.

J Biotechnol. 2014 May 20;178:43-53. doi: 10.1016/j.jbiotec.2014.03.012. Epub 2014 Mar 18.

PMID:
24657347
19.

High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.

Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, Jordan I, Reichl U.

Vaccine. 2014 May 19;32(24):2770-81. doi: 10.1016/j.vaccine.2014.02.016. Epub 2014 Feb 25.

PMID:
24583003
20.

Vaccine production: upstream processing with adherent or suspension cell lines.

Genzel Y, Rödig J, Rapp E, Reichl U.

Methods Mol Biol. 2014;1104:371-93. doi: 10.1007/978-1-62703-733-4_23.

PMID:
24297427

Supplemental Content

Loading ...
Support Center